论文部分内容阅读
目的:对某三级医院抗肿瘤药品不良反应(ADR)进行监测分析,为临床抗肿瘤药物的合理应用提供参考,同时分析ADR呈报情况。方法:对该院2007年1月~2013年12月上报的304例抗肿瘤药物ADR报告结合Excel电子表格和手工筛选方法,进行统计分析。结果:304例ADR中男116例,女188例;40岁以上275例;发生不良反应例数最多的是注射用顺铂79例;ADR临床表现以血液系统、消化系统为主。发现新的不良反应12例;2012年12月份肿瘤科不良反应报告率为1.02%,用回顾性住院患者集中监测法发现不良反应发生率为54.17%。结论:应加强对肿瘤患者ADR的监测工作,改善监测方法,以保证用药安全。
Objective: To monitor and analyze the adverse drug reaction (ADR) in a tertiary hospital, to provide reference for the rational application of clinical anti-cancer drugs and to analyze the status of ADR. METHODS: A total of 304 ADR reports of antitumor drugs reported from January 2007 to December 2013 in the hospital were combined with Excel spreadsheets and manual screening methods for statistical analysis. Results: There were 116 males and 188 females in 304 ADRs and 275 cases older than 40 years old. The most frequent adverse reactions were cisplatin for injection in 79 cases. The clinical manifestations of ADR were mainly blood system and digestive system. 12 cases were found new adverse reactions. The rate of adverse reactions reported in oncology department in December 2012 was 1.02%. The incidence of adverse reactions was 54.17% with the centralized monitoring of retrospective inpatients. Conclusion: The monitoring of ADR in cancer patients should be strengthened and the monitoring methods should be improved to ensure drug safety.